Anti-Bb Antibody (NM8074) Receives US FDA Clearance to Start Clinical Trial in Naïve aHUS Patients (Rare Disease)
30 janv. 2023 08h30 HE
|
Novelmed Therapeutics Inc
-- FDA Clears Initiation of Efficacy Trial in aHUS (Atypical Hemolytic Uremic Syndrome) Patients An Efficacy Trial in Adult aHUS Patients Who Are Naïve to Complement Inhibitor Therapy...
FOMO CORP.’S PURGE VIRUS, LLC PARTNERS WITH RENOWNED HVAC CONTRACTOR FOR INSTALLATION AND SALES OF DISINFECTION TECHNOLOGIES
08 déc. 2020 10h00 HE
|
FOMO CORP.
Chicago, IL, Dec. 08, 2020 (GLOBE NEWSWIRE) -- FOMO CORP. (US OTC: ETFM) announces that its wholly owned subsidiary, Purge Virus, LLC (https://purgevirus.com) has partnered with PVBJ Inc....
Reaching underserved patients in the kidney community: American Kidney Fund expands online resources for rare diseases
06 sept. 2018 11h30 HE
|
American Kidney Fund
ROCKVILLE, Md., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Because many relatively unknown rare diseases can cause permanent damage to the kidneys, the American Kidney Fund (AKF) today announced it has...
Akari Therapeutics Announces R&D Day on April 24, 2017
17 mars 2017 07h00 HE
|
Akari Therapeutics, Plc
NEW YORK and LONDON, March 17, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that it will hold a Research...
Akari Therapeutics to Present at the 29th Annual ROTH Conference
07 mars 2017 07h00 HE
|
Akari Therapeutics, Plc
NEW YORK and LONDON, March 07, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief...
Akari Therapeutics to Attend Upcoming Investor Conferences in February
31 janv. 2017 07h00 HE
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Jan. 31, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that senior management will...
Akari Therapeutics Expands Clinical and Regulatory Teams with Industry Veterans
04 janv. 2017 07h00 HE
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, has expanded its clinical and regulatory teams....
Akari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNH
03 janv. 2017 07h00 HE
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug...
Akari Therapeutics Announces Corporate Update with New Positive Clinical Data and a New Pipeline of Tick Derived and Engineered Proteins
05 déc. 2016 07h00 HE
|
Akari Therapeutics, Plc
-Phase Ib cohorts demonstrate dose effect and additional support for once daily dosing--PAS-Coversin pre-clinical data supports once weekly dosing--Phase II PNH patients identified with data expected...
Akari Therapeutics to Attend Upcoming Investor Conferences In November
11 nov. 2016 07h00 HE
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief...